Baker Bros. Advisors (GP) LLC executed the largest insider purchase in KOD history, acquiring nearly 279,000 shares at $72.39 on September 28, 2026, just days after the stock nearly tripled on positive wet AMD trial data. This high-profile buyback by a major shareholder suggests conviction in the company's valuation following a massive market move.
Price context
The stock has experienced explosive growth, surging 189.26% over the last five days and 143.87% over the past 30 days to reach $91.16, which is just 4.81% below its 52-week high of $95.77. The recent surge was triggered by positive Phase 3 DAYBREAK data announced on September 29, 2026.
Catalysts to watch
1) Upcoming BLA Filing: The company is nearing a Biologics License Application submission for its wet AMD treatment following the positive DAYBREAK data on September 29, 2026. 2) Upcoming Earnings: The next earnings report is scheduled for Q3 2026, which will provide further guidance on the commercialization of Zenkuda and tabirafusp-tedromer. 3) Insider Momentum: This represents the largest insider purchase ever recorded for KOD, signaling strong institutional confidence.
Risks
1) High Short Interest: The stock has a short interest of 26.87% of the float, indicating significant skepticism among traders. 2) Revenue Burn: Recent analysis notes the company is a cash-burning biotech with no revenue, which complicates the valuation and may necessitate a future share offering.
AI-generated context from public data. Not investment advice. Verify before trading.